Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 21 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Batistatou, Anna [Clear All Filters]
(2020).
Genetic mapping of pancreatic cancer by targeted next-generation sequencing e.
ESMO Open. 4(5), e000525.
(2019). Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome..
Clin Breast Cancer. 19(2), 113-125.e4.
(2019).
(2018).
(2018).
(2017).
(2016).
p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015). alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies..
BMC Clin Pathol. 14, 28.
(2014). The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping..
Breast. 23(3), 234-43.
(2014). Thirteen years follow-up of heart myxoma operated patients: what is the appropriate surgical technique?.
J Thorac Dis. 6 Suppl 1, S32-8.
(2014). Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays..
Anticancer Res. 33(5), 2139-45.
(2013).
(2013).
(2013). Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel..
PLoS One. 7(6), e37946.
(2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy..
J Transl Med. 10, 10.
(2012).
(2012).
(2012).
(2011).
(2010).